Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aviceda Therapeutics

Request full access

Harnessing the natural immune system to modulate inflammation with highly selective ligands targeting specific immune cells and diseases

Cambridge, United StatesFounded 2018Biotech & Life Sciences

About Aviceda Therapeutics

Aviceda Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory diseases by leveraging the natural immune system. The company targets specific immune cells using highly selective ligands designed for maximum specificity and efficacy. Aviceda operates in the biopharmaceutical market, serving patients with life-threatening inflammatory conditions. Its business model revolves around the discovery and development of novel drugs, utilizing proprietary high-throughput screening libraries to create synthetic ligands with high specificity and affinity to Siglecs, a family of receptors on immune cells. Aviceda generates revenue through the development and commercialization of these transformative medicines. The company primarily serves the healthcare sector, including patients, healthcare providers, and research institutions.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
Cambridge, United States
Employees
24
Open positions
None listed
Dealroom signal
61.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jan 2025 $208M $830M Longitude Capital · Digitalis Ventures · Jeito Capital · Enavate Sciences ↗
LATE VCOther financing May 2023 $16M $248M Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Aviceda Therapeutics website traffic

Latest recorded traffic for Aviceda Therapeutics is 1.7K monthly website visits, up 41.7% over the last three months. Aviceda Therapeutics's team declined 41.5% over the past year.

Latest monthly visits1.7K 3-month web change+41.7% 1-year team growth-41.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Aviceda Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Aviceda Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later11 investors entered at this stage

  • Omega Funds
  • TCGX
  • Longitude Capital
  • Digitalis Ventures
  • Jeito Capital
  • Enavate Sciences
  • OrbiMed
  • Marshall Wace
  • Logos Capital
  • Catalio Capital Management
  • Aberdeen

Other known investors1 additional known investor

  • Queen's University Belfast
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States92%
🇬🇧 United Kingdom4%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aviceda Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aviceda Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.